en
Scientific article
Open access
English

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

Published inTranslational lung cancer research, vol. 10, no. 4, p. 1960-1968
Publication date2021
Abstract

Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated with a poor prognosis. A number of therapeutic options are available for patients with Stage III N2 NSCLC, including surgery [with neoadjuvant or adjuvant chemotherapy (CTx)/neoadjuvant chemoradiotherapy (CRT)] or CRT potentially followed by adjuvant immunotherapy. We have no clear evidence demonstrating a significant survival benefit for either of these approaches, the selection between treatments is not always straightforward and can come down to physician and patient preference. The very heterogeneous definition of resectability of N2 disease makes the decision-making process even more complex.

Keywords
  • Non-small cell lung cancer (NSCLC)
  • Decision-making
  • Radiotherapy
  • Stage III N2 lung cancer
  • Surgery
Citation (ISO format)
GLATZER, Markus et al. Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. In: Translational lung cancer research, 2021, vol. 10, n° 4, p. 1960–1968. doi: 10.21037/tlcr-20-1210
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal2218-6751
95views
30downloads

Technical informations

Creation06/09/2021 3:30:00 PM
First validation06/09/2021 3:30:00 PM
Update time03/16/2023 1:37:26 AM
Status update03/16/2023 1:37:24 AM
Last indexation10/19/2023 4:35:18 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack